Alivus Life Sciences Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Alivus Life Sciences share price target 2026 is Rs 1,250, based on analyst estimates and the FY27 earnings recovery thesis. Q4 FY26 results announced May 30, 2026 are the immediate trigger for re-rating Alivus Life Sciences (NSE: ALIVUS). This article covers the complete Alivus Life Sciences share price target analysis including sector tailwinds, key risks, and the bull and bear case scenarios.

Click Here – Get Free Investment Predictions

Alivus Life Sciences Company Overview

Alivus Life Sciences (NSE: ALIVUS) is a pharmaceutical API company producing bulk drugs and intermediates with DSIR-recognised R&D and WHO-GMP manufacturing. At CMP Rs 1,036 against a 52 week range of Rs 735 to Rs 1,675, the stock trades at a meaningful discount to its 52 week high. Market capitalisation stands at Rs 1,554 crore with a trailing PE of sector-average.

Parameter	Value
NSE Ticker	ALIVUS
Sector	Pharmaceutical APIs and Life Sciences
CMP (May 30, 2026)	Rs 1,036
52 Week High	Rs 1,675
52 Week Low	Rs 735
Market Cap	Rs 1,554 crore
Trailing PE	sector-average
12-Month Analyst Target	Rs 1,250
Bull Case Target	Rs 1,500
Bear Case Target	Rs 830

Why Is the Alivus Life Sciences Share Price Target Set at Rs 1,250 for 2026

FY27 Earnings Delivery and Revenue Acceleration

The Alivus Life Sciences share price target 2026 of Rs 1,250 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results confirming the recovery trajectory are the most direct catalyst for re-rating from CMP Rs 1,036 toward the Alivus Life Sciences share price target of Rs 1,250.

Structural Sector Tailwinds in Pharmaceutical APIs and Life Sciences

The Pharmaceutical APIs and Life Sciences sector is expanding on the back of India’s strong domestic demand, PLI scheme support, and rising corporate investment. Alivus Life Sciences’s market position creates a structural growth runway supporting the Alivus Life Sciences share price target consensus of Rs 1,250 and the bull case of Rs 1,500.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle, which began in early 2026, reduces Alivus Life Sciences’s borrowing costs and stimulates demand across end markets. Lower interest costs improve EPS trajectory, directly supporting the Alivus Life Sciences share price target 2026 of Rs 1,250.

Union Budget 2026-27 Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Alivus Life Sciences’s Pharmaceutical APIs and Life Sciences operations, improving the probability of achieving the Alivus Life Sciences share price target of Rs 1,250.

Improving FII Flows Post the April 2026 Tariff Shock

As global macro conditions normalise post the April 2026 US tariff event, FII flows into quality Indian equities are recovering through FY27. At sector-average PE, Alivus Life Sciences is positioned as a beneficiary of institutional reallocation supporting the path to Rs 1,250.

Alivus Life Sciences Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Alivus Life Sciences Share Price Target: 3 to 6 Months

The near-term Alivus Life Sciences share price target is anchored to support near the 52 week low of Rs 735. A confirmed Q4 FY26 earnings recovery and positive FY27 guidance are the triggers for an initial 10 to 15 percent re-rating toward Rs 1,250.

12-Month Alivus Life Sciences Share Price Target 2026

The 12-month Alivus Life Sciences share price target 2026 is Rs 1,250, implying approximately 20 percent upside from CMP Rs 1,036. This base case assumes in-line FY27 earnings delivery and partial FII flow normalisation. Track live on NSE ticker ALIVUS.

Long Term Alivus Life Sciences Share Price Target: FY27 to FY28

For investors with a 2 to 3 year horizon, the long-term Alivus Life Sciences share price target is Rs 1,500 in the bull case, assuming full earnings delivery through FY27 to FY28 and sector re-rating in the Pharmaceutical APIs and Life Sciences space.

Bull Case and Bear Case for the Alivus Life Sciences Share Price Target

Bull Case Alivus Life Sciences Share Price Target: Rs 1,500

The bull case for the Alivus Life Sciences share price target of Rs 1,500 materialises when FY27 earnings beat analyst estimates, sector tailwinds accelerate, and FII flows return strongly to Indian equities. The stock re-rates toward higher peer multiples, making Rs 1,500 achievable within FY28.

Bear Case Alivus Life Sciences Share Price Target: Rs 830

The bear case sees the Alivus Life Sciences share price target testing Rs 830 if FY27 earnings disappoint and FII outflows persist. At Rs 830, the stock approaches the 52 week low support of Rs 735, requiring a full reassessment of the investment thesis.

Scenario	Target	Key Conditions
Bull Case	Rs 1,500	FY27 earnings beat, sector re-rating, strong FII inflows
Base Case	Rs 1,250	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 830	FY27 earnings miss, guidance cut, sustained FII outflows

Key Risks to the Alivus Life Sciences Share Price Target 2026

US Tariff and Global Macro Risk

The 26 percent US reciprocal tariff announced April 2, 2026 triggered FII outflows across Indian equities. Prolonged trade tension or a global demand slowdown remains the most prominent macro risk to the Alivus Life Sciences share price target 2026 of Rs 1,250.

Valuation and Earnings Miss Risk

Any FY27 earnings miss or guidance cut could trigger multiple compression, posing a direct risk to the Alivus Life Sciences share price target of Rs 1,250. Monitoring quarterly results closely is essential for investors in Alivus Life Sciences.

Competitive Pressure in Pharmaceutical APIs and Life Sciences

Intensifying competition in the Pharmaceutical APIs and Life Sciences sector could compress Alivus Life Sciences’s pricing power and market share over the medium term, which must be factored into any assessment of the Alivus Life Sciences share price target of Rs 1,250.

FII Selling Pressure and Liquidity Risk

Sustained FII outflows from Indian equities can delay re-rating toward the Alivus Life Sciences share price target of Rs 1,250 regardless of company-level operational improvement through FY27.

How to Invest in Alivus Life Sciences

Check the Univest Screener for live data

Begin by reviewing Alivus Life Sciences’s Q4 FY26 results, annual report, and FY27 guidance statements before forming a view on the Alivus Life Sciences share price target of Rs 1,250. Focus on revenue growth trajectory, margin trends, and management commentary on sector headwinds and opportunities.

Open a Demat and trading account with a SEBI registered stockbroker to buy Alivus Life Sciences (NSE: ALIVUS) with full regulatory protection. Ensure KYC is complete and understand the Pharmaceutical APIs and Life Sciences sector dynamics before executing any position.

Plan your entry near the 52 week low support of Rs 735. A confirmed Q4 FY26 earnings uptick and positive FY27 guidance would strengthen the entry case for the Alivus Life Sciences share price target of Rs 1,250. Set a disciplined stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio to manage concentration risk, especially in smaller-cap Pharmaceutical APIs and Life Sciences companies where liquidity and volatility can amplify losses.

Always consult a SEBI registered financial advisor before investing based on any Alivus Life Sciences share price target estimate. A registered advisor personalises recommendations based on your risk profile and financial goals. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Alivus Life Sciences’s live price and get daily stock recommendations.

FAQs on Alivus Life Sciences Share Price Target 2026

What is the Alivus Life Sciences share price target for 2026?

Ans. The Alivus Life Sciences share price target 2026 is Rs 1,250, implying approximately 20 percent upside from CMP Rs 1,036. The bull case target is Rs 1,500 and the bear case target is Rs 830.

Is Alivus Life Sciences a good buy at the current price of Rs 1,036?

Ans. At Rs 1,036, Alivus Life Sciences offers potential upside to the share price target of Rs 1,250 if FY27 earnings recover as projected. Consult a SEBI registered financial advisor before making any investment decision.

What is the 52 week high and low of Alivus Life Sciences?

Ans. The 52 week high of Alivus Life Sciences is Rs 1,675 and the 52 week low is Rs 735. At CMP Rs 1,036, the stock offers upside potential toward the 12-month share price target of Rs 1,250.

What are the key risks to the Alivus Life Sciences share price target 2026?

Ans. Key risks to the Alivus Life Sciences share price target of Rs 1,250 include an FY27 earnings miss, US tariff-driven FII outflows, competitive pressure in Pharmaceutical APIs and Life Sciences, and broader market volatility.

What are the main catalysts for the Alivus Life Sciences share price target?

Ans. Primary catalysts include FY27 PAT recovery, structural tailwinds in Pharmaceutical APIs and Life Sciences, RBI rate cut support, Union Budget 2026-27 policy uplift, and FII flow normalisation into Indian equities through FY27.

What is the Alivus Life Sciences share price target for 2027?

Ans. The long-term Alivus Life Sciences share price target for FY27 to FY28 is Rs 1,500 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.